Search Results - "Tsikkinis, A."

Bladder-Preserving Combined-Modality Therapy: What Is Coming Next? A Critical Analysis of Phase 2-3 Trials of the ClinicalTrials.gov Database by Tsikkinis, A, Cihoric, N, Ghadjar, P, Loessl, K, Aebersold, D.M, Pra, A. Dal

Get full text

Analysis of Clinical Trials in Radiation Oncology: A Systematic Characterization of the Clinicaltrials.gov Database by Cihoric, N, Tsikkinis, A, Aebersold, D.M, Lössl, K, Zaugg, K

Get full text

The hormonal profile of benign breast disease by Samoli, E, Trichopoulos, D, Lagiou, A, Zourna, P, Georgila, C, Minaki, P, Barbouni, A, Vassilarou, D, Tsikkinis, A, Sfikas, C, Spanos, E, Lagiou, P

“…Background: Limited information exists about the endocrine milieu of benign breast disease (BBD), a documented breast cancer risk factor. We compared blood…”
Get full text

Expression of estrogen receptors in non-malignant mammary tissue modifies the association between insulin-like growth factor 1 and breast cancer risk by Samoli, E., Lagiou, A., Zourna, P., Barbouni, A., Georgila, C., Tsikkinis, A., Vassilarou, D., Minaki, P., Sfikas, C., Spanos, E., Trichopoulos, D., Lagiou, P.

“…We have found evidence in support of an interaction of IGF-1 with the expression of estrogen receptor &agr; (ER&agr;) in the non-malignant mammary tissue in…”
Get full text

A comparison of hormonal profiles between breast cancer and benign breast disease: a case–control study by Lagiou, P., Samoli, E., Lagiou, A., Zourna, P., Barbouni, A., Georgila, C., Tsikkinis, A., Vassilarou, D., Minaki, P., Sfikas, C., Spanos, E., Trichopoulos, D.

“…Benign breast disease (BBD), particularly proliferative BBD, is an established breast cancer risk factor. However, there has been no systematic attempt to…”
Get full text

EP-1683: Clinical trials in 15 malignancies with highest mortality rate on global scale by Vlaskou Badra, E., Tsikkinis, A., Cihoric, N.

Get full text

PO-1040 Partial breast irradiation with interstitial multicatheter HDR BT for breast cancer by Cihoric, N., Tsikkinis, A., Terribilini, D., Aebersold, D.M., Lössl, K.

Get full text

PO-1296 Usage of PET/CT as a post-treatment surveillance strategy in locoregionally advanced cervical cancer by Cihoric, N., Astrid Elisabeth, H., Imboden, S., Aebersold, D., Blatti, M., Tsikkinis, A., Kristina, L.

Get full text

EP-1506 Multi-institutional treatment and management of cervical cancer patients by Tsikkinis, A., Cihoric, N., Badra, E. Vlaskou, Aebersold, D., Lössl, K.

Get full text

EP-1504 Role of PET/CT in assessing treatment response of cervical cancer after definitive RadioChemotherapy by Tsikkinis, A., Badra, E. Vlaskou, Cihoric, N., Aebersold, D., Lössl, K.

Get full text

Cisplatin and Gemcitabine Combined with Highly Conformal External Beam Radiation Therapy in the Treatment of Cervical Cancer Patients Result in Low Toxicity and Promising Outcome by Cihoric, N., Glatzer, M., Badra, E. Vlaskou, Tsikkinis, A., Lössl, K.

Get full text

Microsatellite instability and loss of heterozygosity in primary breast tumours by Sourvinos, G, Kiaris, H, Tsikkinis, A, Vassilaros, S, Spandidos, D A

“…Allelic imbalance or loss of heterozygosity (LOH) studies have been used extensively to identify regions on chromosomes that may contain putative tumour…”
Get more information

A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer by Boukovala, Myrto, Spetsieris, Nicholas, Weldon, Justin A., Tsikkinis, Alexandros, Hoang, Anh, Aparicio, Ana, Tu, Shi-Ming, Araujo, John C., Zurita, Amado J., Corn, Paul G., Pagliaro, Lance, Kim, Jeri, Wang, Jennifer, Subudhi, Sumit K., Tannir, Nizar M., Logothetis, Christopher J., Troncoso, Patricia, Wen, Sijin, Efstathiou, Eleni

“…The unmet need for predictive biomarkers emerged from the unpredictable pattern of response to androgen signalling inhibition in metastatic…”
Get full text

Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC) by Efstathiou, E., Tsikkinis, A., Wen, S., Tapia, E. Li Ning, Hoang, A., Aparicio, A., Tu, S.-M., Rangel, G., Troncoso, P., Corn, P., Araujo, J., Logothetis, C.

Get full text

A phase II trial of Abiraterone followed by randomization to addition of Dasatinib or Sunitinib in men with metastatic castration resistant prostate cancer by Spetsieris, N., Boukovala, M., Weldon, J. A., Tsikkinis, A., Hoang, A., Aparicio, A., Tu, SM, Araujo, J.C., Zurita, A. J., Corn, P., Pagliaro, L., Kim, J., Wang, J., Subudhi, S. K., Tannir, N., Logothetis, C. J., Troncoso, P., Wang, X., Wen, S., Efstathiou, E.

“…The Src pathway and neoangiogenesis have been implicated in prostate cancer progression. In an open-label, randomized, phase II study, no difference was…”
Get full text

Expression of ras Rb1 and p53 proteins in human breast cancer by Spandidos, D A, Karaiossifidi, H, Malliri, A, Linardopoulos, S, Vassilaros, S, Tsikkinis, A, Field, J K

“…The ras, Rb and p53 genes have been implicated in the development of human breast cancer. Qualitative or quantitative changes in the expression of the ras p21…”
Get more information

Rare case of a large tumour of the breast area in 41-year-old male by Korfias, D., Tsikkinis, A., Kondi-Paphitis, A.

“…Aim-Background Tumours of the anterior thoracic wall and especially of the breast area mainly concern mammary gland tumours. Other breast neoplasms usually…”
Get full text

Elevated expression of AP-1 activity in human breast tumors as compared to normal adjacent tissue by Linardopoulos, S, Malliri, A, Pintzas, A, Vassilaros, S, Tsikkinis, A, Spandidos, D A

“…The levels of AP-1 activity in human breast lesions and in adjacent normal tissue were studied by a gel retardation assay. A thirty nucleotide long consensus…”
Get more information

Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database by Tsikkinis, Alexandros, Cihoric, Nikola, Giannarini, Gianluca, Hinz, Stefan, Briganti, Alberto, Wust, Peter, Ost, Piet, Ploussard, Guillaume, Massard, Christophe, Surcel, Cristian I, Sooriakumaran, Prasanna, Isbarn, Hendrik, De Visschere, Peter J.L, Futterer, Jurgen J, van der Bergh, Roderick C.N, Dal Pra, Alan, Aebersold, Daniel M, Budach, Volker, Ghadjar, Pirus

“…Abstract Background It is not easy to overview pending phase 3 trials on prostate cancer (PCa), and awareness of these trials would benefit clinicians…”
Get full text

A randomised clinical trial of primary chemotherapy (PC) with taxol + epirubicin (TE) V. 5-FU + epirubicin + cyclophosphamide (FEC) in stage IIIA breast cancer: A preliminary report by Malamos, N., Papadiamantis, I., Andonopoulos, M., Tsikkinis, A., Kosmas, H., Pallis, L., Kouri, E., Sfikas, K., Vassilaros, St

Get full text